Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 7681 results

  1. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266

    In development [GID-TA11248] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  2. Digital technologies to support self-management of COPD: early value assessment

    In development [GID-HTE10030] Expected publication date: 19 December 2024

    Health technology evaluations
    In development

  3. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  5. Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults

    In development [GID-IPG10362] Expected publication date: 29 January 2025

    Interventional procedures guidance
    In development

  6. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development [GID-TA11087] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Semaglutide for treating non-alcoholic steatohepatitis with significant liver fibrosis ID6458

    Awaiting development [GID-TA11477] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232

    Awaiting development [GID-TA11230] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: 09 January 2025

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    Awaiting development [GID-TA11440] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development [GID-TA11470] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Benralizumab for previously treated severe nasal polyps [ID1659]

    Awaiting development [GID-TA10818] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development [GID-TA11307] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]

    In development [GID-TA11042] Expected publication date: TBC

    Technology appraisal guidance
    In development